LENZ Therapeutics Q2 revenue rises on VIZZ sales
LENZ Therapeutics Q2 revenue rises on VIZZ sales
Overview
U.S. eye care pharma's Q2 2026 revenue reached $5.5 mln, driven by VIZZ sales and licenses
Company posted Q2 net loss of $31.9 mln amid higher launch and marketing expenses
VIZZ product sales rose 9% over Q1 2026; telehealth and TV campaigns launched in July
Outlook
Company did not provide specific guidance or forecasts for the current or future periods in press release
Result Drivers
PATIENT REFILLS - Over 60% of ePharmacy patients purchased multiple monthly packs since launch, with early cohorts tracking to five packs annually, per CEO Eef Schimmelpennink
LICENSE REVENUE - Q2 license revenue included milestone and sublicense payments from international commercialization agreements
Company press release: ID:nGNX95cPzP
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $31.92 mln |
|
Q2 Income from Operations |
| -$34.17 mln |
|
Q2 Operating Expenses |
| $39.66 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for LENZ Therapeutics, Inc. is $25.50, about 375.7% above its August 10 closing price of $5.36
Reuters Recommended Reads
Aug 11 - Eye care company Alcon raises margin outlook, shares jump
Aug 10 - Telehealth platform Hims & Hers swings to Q2 net loss as margin pressure offsets revenue growth
Aug 10 - Harrow Q2 revenue slightly beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)